Cyclin D as a therapeutic target in cancer
暂无分享,去创建一个
Robert L. Sutherland | Andrew Stone | R. Sutherland | E. Musgrove | C. Caldon | A. Stone | C. Elizabeth Caldon | Elizabeth A. Musgrove | Jane Barraclough | J. Barraclough | Andrew Stone | C. E. Caldon | Jane Barraclough
[1] Joshua E. Elias,et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers , 2011, Nature.
[2] T. Hudson,et al. Somatic variation and cancer: therapies lost in the mix , 2011, Human Genetics.
[3] Edward S. Kim,et al. Cotargeting Cyclin D1 Starts a New Chapter in Lung Cancer Prevention and Therapy , 2011, Cancer Prevention Research.
[4] E. Dmitrovsky,et al. Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models , 2011, Cancer Prevention Research.
[5] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[6] K. Wilner,et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) , 2011, British Journal of Cancer.
[7] M. Schlissel,et al. Forced Expression of Cyclin-Dependent Kinase 6 Confers Resistance of Pro-B Acute Lymphocytic Leukemia to Gleevec Treatment , 2011, Molecular and Cellular Biology.
[8] M. Kitagawa,et al. Coordinated regulation of differentiation and proliferation of embryonic cardiomyocytes by a jumonji (Jarid2)-cyclin D1 pathway , 2011, Development.
[9] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[10] V. Velculescu,et al. Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer , 2011, Clinical Cancer Research.
[11] M. Socinski,et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] H. Elsaleh,et al. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. , 2010, Cancer research.
[13] M. Herlyn,et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. , 2010, Cancer cell.
[14] H. Rui,et al. RB-pathway disruption in breast cancer , 2010, Cell cycle.
[15] H. Clevers,et al. Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. , 2010, Cancer research.
[16] L. Chodosh,et al. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2 , 2010, Oncogene.
[17] Y. Kuwahara,et al. Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3β-mediated cyclin D1 overexpression , 2010, Oncogene.
[18] E. Knudsen,et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure , 2010, Oncogene.
[19] M. Barbacid,et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. , 2010, Cancer cell.
[20] Kwok-Kin Wong,et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. , 2010, The Journal of clinical investigation.
[21] Yonghong Xiao,et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.
[22] D. Berney,et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. , 2010, The American journal of pathology.
[23] Xiaopei Huang,et al. Role of Cdk4 in lymphocyte function and allergen response , 2010, Cell cycle.
[24] R. Bosotti,et al. Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study , 2010, Molecular Cancer Therapeutics.
[25] P. Lienau,et al. Abstract 3883: Pharmacologic profile of the oral novel pan-CDK inhibitor BAY 1000394 in chemosensitive and chemorefractory tumor models , 2010 .
[26] M. Prados,et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.
[27] A. Troxel,et al. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. , 2010, Anticancer research.
[28] Chenguang Wang,et al. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. , 2010, Cancer research.
[29] S. Bao,et al. Methylation of Ribosomal Protein S10 by Protein-arginine Methyltransferase 5 Regulates Ribosome Biogenesis* , 2010, The Journal of Biological Chemistry.
[30] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[31] Clifford A. Meyer,et al. Transcriptional role of cyclin D1 in development revealed by a genetic–proteomic screen , 2010, Nature.
[32] P. Hinds,et al. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. , 2010, Cancer cell.
[33] Sinan Zhu,et al. Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance , 2010, Clinical Medicine Insights. Oncology.
[34] S. Sen,et al. Cyclin D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on estrogen receptor alpha-mediated transcription. , 2009, International journal of oncology.
[35] M. Stratton,et al. A census of amplified and overexpressed human cancer genes , 2010, Nature Reviews Cancer.
[36] P. Kaldis,et al. Cdk2 and Cdk4 Regulate the Centrosome Cycle and Are Critical Mediators of Centrosome Amplification in p53-Null Cells , 2009, Molecular and Cellular Biology.
[37] W. Gu,et al. Suppression of cancer cell growth by promoting cyclin D1 degradation. , 2009, Molecular cell.
[38] Shih-Yin Tsai,et al. Emerging roles of E2Fs in cancer: an exit from cell cycle control , 2009, Nature Reviews Cancer.
[39] J. Dering,et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.
[40] H. Inoue,et al. Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells , 2009, Molecular carcinogenesis.
[41] E. Hanse,et al. Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo , 2009, Cell cycle.
[42] H. Rui,et al. Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer , 2009, Clinical Cancer Research.
[43] Robert L. Sutherland,et al. Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.
[44] James Rosinski,et al. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients , 2009, Molecular Cancer Therapeutics.
[45] J. Diehl,et al. Nuclear cyclin D1: An oncogenic driver in human cancer , 2009, Journal of cellular physiology.
[46] T. Brunner,et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. , 2009, Cancer research.
[47] A. Giordano,et al. Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.
[48] Gordon B Mills,et al. Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer , 2009, Clinical Cancer Research.
[49] H. Rui,et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome , 2009, Oncogene.
[50] Rajiv Chopra,et al. Crystal structure of human CDK4 in complex with a D-type cyclin , 2009, Proceedings of the National Academy of Sciences.
[51] M. E. M. Noble,et al. The structure of CDK4/cyclin D3 has implications for models of CDK activation , 2009, Proceedings of the National Academy of Sciences.
[52] W. Steward,et al. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours , 2009, Cancer Chemotherapy and Pharmacology.
[53] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[54] G. Hu,et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. , 2009, Cancer research.
[55] K. Knudsen,et al. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer , 2008, Oncogene.
[56] M. Wang,et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy , 2009, Leukemia.
[57] Y. Mo,et al. Systematic validation of predicted microRNAs for cyclin D1 , 2009, BMC Cancer.
[58] J. Li,et al. Cyclin D1 in low-dose radiation-induced adaptive resistance , 2008, Oncogene.
[59] T. Mok,et al. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. , 2008, Human pathology.
[60] N. Munshi,et al. RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms , 2008 .
[61] Mauro Biffoni,et al. The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.
[62] H. Ozçelik,et al. Cyclin D1 Pro241Pro (CCND1-G870A) Polymorphism Is Associated with Increased Cancer Risk in Human Populations: A Meta-Analysis , 2008, Cancer Epidemiology Biomarkers & Prevention.
[63] C. Bassing,et al. Genotoxic Stress-Induced Cyclin D1 Phosphorylation and Proteolysis Are Required for Genomic Stability , 2008, Molecular and Cellular Biology.
[64] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[65] K. Knudsen,et al. Tailoring to RB: tumour suppressor status and therapeutic response , 2008, Nature Reviews Cancer.
[66] Hong Wu,et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.
[67] T. Tiganis,et al. DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression. , 2008, Cancer cell.
[68] Gabriel Sanchez,et al. Coupled alteration of transcription and splicing by a single oncogene: Boosting the effect on cyclin D1 activity , 2008, Cell cycle.
[69] K. Kaestner,et al. Distinct proliferative and transcriptional effects of the D-type cyclins in vivo , 2008, Cell cycle.
[70] S. Chen‐Kiang,et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. , 2008, Cancer research.
[71] A. Rustgi,et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. , 2008, Cancer cell.
[72] R. Greil,et al. Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy , 2008, Clinical Cancer Research.
[73] G. Prendergast,et al. Alternate Cyclin D1 mRNA Splicing Modulates p27KIP1 Binding and Cell Migration* , 2008, Journal of Biological Chemistry.
[74] James M. Roberts,et al. CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .
[75] A. Friedman,et al. Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. , 2007, Blood.
[76] Andrew R. Green,et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.
[77] A. Rustgi,et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. , 2007, Genes & development.
[78] E. Campo,et al. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.
[79] Anne-Marie Duchemin,et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. , 2007, Blood.
[80] Hanzhou Wang,et al. Cyclin D3/CDK11p58 Complex Is Involved in the Repression of Androgen Receptor , 2007, Molecular and Cellular Biology.
[81] R. Berro,et al. Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells , 2007, Oncogene.
[82] P. Kaldis,et al. Cell-specific responses to loss of cyclin-dependent kinases , 2007, Oncogene.
[83] K. Wilner,et al. A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991 , 2007 .
[84] A. Tan,et al. A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs) , 2007 .
[85] Adrian Wiestner,et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. , 2007, Blood.
[86] J. Alao,et al. Molecular Cancer BioMed Central Review The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention , 2007 .
[87] A. Giordano,et al. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo , 2007, Oncogene.
[88] K. Knudsen,et al. Impact of differential cyclin D1 expression and localisation in prostate cancer , 2007, British Journal of Cancer.
[89] Oliver Gautschi,et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. , 2007, Lung Cancer.
[90] T. Shioda,et al. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. , 2006, Cancer research.
[91] A. Thompson,et al. Cyclin D1 and breast cancer. , 2006, Breast.
[92] E. Pérez-Payá,et al. Identification of an Hexapeptide That Binds to a Surface Pocket in Cyclin A and Inhibits the Catalytic Activity of the Complex Cyclin-dependent Kinase 2-Cyclin A* , 2006, Journal of Biological Chemistry.
[93] Qing Xiang,et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials , 2006, Molecular Cancer Therapeutics.
[94] Paul J. Smith,et al. Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents , 2006 .
[95] M. Lisanti,et al. Cyclin D1 induction of cellular migration requires p27(KIP1). , 2006, Cancer research.
[96] J. Herman,et al. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1 , 2006, Oncogene.
[97] G. Peters,et al. Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all , 2006, Nature Reviews Molecular Cell Biology.
[98] D. Sabatini. mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.
[99] P. Nowell,et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. , 2006, Blood.
[100] M. Monden,et al. Antisense to Cyclin D1 Inhibits Vascular Endothelial Growth Factor–Stimulated Growth of Vascular Endothelial Cells: Implication of Tumor Vascularization , 2006, Clinical Cancer Research.
[101] Wei Li,et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma , 2006, Pathology.
[102] Chenguang Wang,et al. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[103] S. Ely,et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. , 2006, Cancer research.
[104] A. Joe,et al. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.
[105] Anping Li,et al. Cyclin D1 Determines Mitochondrial Function InVivo , 2006, Molecular and Cellular Biology.
[106] U. Luecking,et al. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[107] F. Liu,et al. Cyclin D1-Cdk4 Induce Runx2 Ubiquitination and Degradation* , 2006, Journal of Biological Chemistry.
[108] Anping Li,et al. Cyclin D1 Regulates Cellular Migration through the Inhibition of Thrombospondin 1 and ROCK Signaling , 2006, Molecular and Cellular Biology.
[109] Robin L. Jones,et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.
[110] G. Shapiro,et al. Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] C. Haiman,et al. Cyclin D1: polymorphism, aberrant splicing and cancer risk , 2006, Oncogene.
[112] F. Cavalli,et al. Update on the molecular biology of mantle cell lymphoma , 2006, Hematological oncology.
[113] J. Celestino,et al. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma , 2006, International Journal of Gynecologic Cancer.
[114] C. Haiman,et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[115] E. Musgrove. Cyclins: Roles in mitogenic signaling and oncogenic transformation , 2006, Growth factors.
[116] Yan Geng,et al. Requirement for CDK4 kinase function in breast cancer. , 2006, Cancer cell.
[117] Tiansen Li,et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. , 2006, Cancer cell.
[118] Y. Xiong,et al. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. , 2005, Cancer research.
[119] Jacinto J. Regalado,et al. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma , 2005, International journal of experimental pathology.
[120] E. Dmitrovsky,et al. Bexarotene and erlotinib for aerodigestive tract cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] L. Fajas,et al. Cyclin D3 Promotes Adipogenesis through Activation of Peroxisome Proliferator-Activated Receptor γ , 2005, Molecular and Cellular Biology.
[122] C P Neal,et al. Molecular prognostic markers in pancreatic cancer: a systematic review. , 2005, European journal of cancer.
[123] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] H. Heng,et al. Overexpression of Cyclin D1 Promotes Tumor Cell Growth and Confers Resistance to Cisplatin-Mediated Apoptosis in an Elastase-myc Transgene–Expressing Pancreatic Tumor Cell Line , 2005, Clinical Cancer Research.
[125] Daniela S Krause,et al. Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.
[126] A. Papanikolaou,et al. Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] Mahadev Rao,et al. Cyclin D1 Inhibits Peroxisome Proliferator-activated Receptor γ-mediated Adipogenesis through Histone Deacetylase Recruitment* , 2005, Journal of Biological Chemistry.
[128] M. Morris,et al. Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation* , 2005, Journal of Biological Chemistry.
[129] P. Hinds,et al. Multiple Functions of D-Type Cyclins Can Antagonize pRb-Mediated Suppression of Proliferation , 2005, Cell cycle.
[130] W. Lingle,et al. Short Term Cyclin D1 Overexpression Induces Centrosome Amplification, Mitotic Spindle Abnormalities, and Aneuploidy* , 2005, Journal of Biological Chemistry.
[131] L. Skoog,et al. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance , 2005, Breast Cancer Research and Treatment.
[132] James M. Roberts,et al. Regulation of the cytoskeleton: an oncogenic function for cdk inhibitors? , 2004, Nature Reviews Cancer.
[133] Chenguang Wang,et al. Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.
[134] R. Sutherland,et al. Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines , 2004, Clinical Cancer Research.
[135] James M. Roberts,et al. Living with or without cyclins and cyclin-dependent kinases. , 2004, Genes & development.
[136] D. Toncheva,et al. Tissue Microarray Analysis of Cyclin D1 Gene Amplification and Gain in Colorectal Carcinomas , 2004, Tumor Biology.
[137] N. Pryer,et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.
[138] K. Akashi,et al. Mouse Development and Cell Proliferation in the Absence of D-Cyclins , 2004, Cell.
[139] Pierre Dubus,et al. Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.
[140] S. Steinberg,et al. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[141] Fang Liu,et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads , 2004, Nature.
[142] J. Cigudosa,et al. Molecular alterations associated with cyclin d1 overexpression in endometrial cancer , 2004, International journal of cancer.
[143] L. Rydén,et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.
[144] J. Lamb,et al. The activities of cyclin D1 that drive tumorigenesis. , 2004, Trends in molecular medicine.
[145] David N Louis,et al. The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer. , 2004, The American journal of pathology.
[146] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[147] A. Ferrando,et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. , 2003, Cancer cell.
[148] J. Minna,et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[149] J. Cigudosa,et al. Cyclin D1 gene (CCND1) mutations in endometrial cancer , 2003, Oncogene.
[150] T. Golub,et al. A Mechanism of Cyclin D1 Action Encoded in the Patterns of Gene Expression in Human Cancer , 2003, Cell.
[151] David Hardisson,et al. Molecular pathogenesis of head and neck squamous cell carcinoma , 2003, European Archives of Oto-Rhino-Laryngology.
[152] Amanda Y. Chan,et al. Cyclin D1 governs adhesion and motility of macrophages. , 2003, Molecular Biology of the Cell.
[153] R. Hruban,et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[154] C. Chomienne,et al. Cyclin D3 Is a Cofactor of Retinoic Acid Receptors, Modulating Their Activity in the Presence of Cellular Retinoic Acid-binding Protein II* , 2003, The Journal of Biological Chemistry.
[155] L. Staudt,et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.
[156] O. Coqueret. Linking cyclins to transcriptional control. , 2002, Gene.
[157] A. Lassar,et al. Cyclin D-cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation. , 2002, Genes & development.
[158] Richard Simon,et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[159] H. Ropers,et al. Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis. , 2002, Journal of cell science.
[160] Y. Geng,et al. Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.
[161] O. Jänne,et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. , 2001, Molecular endocrinology.
[162] S. Weitzman,et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. , 2001, Cancer research.
[163] R. Bronson,et al. Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[164] D. W. Fry,et al. Cell Cycle and Biochemical Effects of PD 0183812 A POTENT INHIBITOR OF THE CYCLIN D-DEPENDENT KINASES CDK4 AND CDK6* , 2001 .
[165] W. Sellers,et al. Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity , 2000, Oncogene.
[166] J. McKay,et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer , 2000, International journal of cancer.
[167] A H Calvert,et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. , 2000, Journal of medicinal chemistry.
[168] Y. Yarden,et al. Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.
[169] K. Branigan,et al. Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells , 1999, British Journal of Cancer.
[170] P. Pandolfi,et al. Targeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27Kip1 Activity , 1999, Molecular and Cellular Biology.
[171] R. Sutherland,et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[172] R. Blamey,et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[173] M. Korc,et al. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. , 1999, Cancer research.
[174] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[175] W. Cavenee,et al. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. , 1999, Cancer research.
[176] M. Ewen,et al. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[177] D. Germain,et al. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer , 1999, Oncogene.
[178] R. Buckle,et al. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. , 1998, Genes & development.
[179] Robert L Sutherland,et al. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells , 1998, Oncogene.
[180] R. Sutherland,et al. Differential Phosphorylation of T-47D Human Breast Cancer Cell Substrates by D1-, D3-, E-, and A-type Cyclin-CDK Complexes* , 1997, The Journal of Biological Chemistry.
[181] M. Ewen,et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 , 1997, Molecular and cellular biology.
[182] R. Bernards,et al. CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.
[183] C. Smythe,et al. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 , 1997, Current Biology.
[184] W. Sellers,et al. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors , 1996, Molecular and cellular biology.
[185] J. Bartek,et al. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity , 1995, Molecular and cellular biology.
[186] Emma Lees,et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.
[187] J. Bartek,et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1 , 1994, The Journal of cell biology.
[188] E. Harlow,et al. Identification of G1 kinase activity for cdk6, a novel cyclin D partner , 1994, Molecular and cellular biology.
[189] Steven K. Hanks,et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins , 1992, Cell.